The mid-stage study evaluated the drug, simtuzumab, in combination
with chemotherapy, against a placebo plus chemotherapy, in
previously untreated patients with advanced pancreatic cancer.
The study failed its main goal of improving
progression-free-survival (PFS). There was no statistically
significant difference in PFS between patients on simtuzumab and
those on the placebo, Gilead said on Wednesday.
Simtuzumab is also being tested for use in colorectal cancer,
myelofibrosis, idiopathic pulmonary fibrosis and liver fibrosis.
Last week, Gilead said the next generation version of its $84,000
hepatitis C drug, Sovaldi, already under fire for its
record-breaking costs, was going to be even more expensive.
Separately, the biotechnology company also licensed Sovaldi to seven
India-based drugmakers that will sell far cheaper versions of the
drug in 91 developing nations.
Foster City, California-based Gilead's stock was little changed at
$105.14 in premarket trading on Wednesday. The stock closed at
$104.76 on Tuesday.
(Reporting by Natalie Grover in Bangalore; Editing by Sriraj
Kalluvila and Simon Jennings)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column]